Vendor Intelligence Report: Alpha-Gen

Published 3 Jul 2026. 27-page investigative report on who is behind Alpha-Gen: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 3 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Alpha-Gen is an active storefront with a weak public verification layer. Across 30 Finnrick lab tests the record is 13 pass / 17 fail, an overall pass rate of 43%. The results are uneven enough that Alpha-Gen should be treated as a product-by-product decision, and the dated testing trail should not be mistaken for current-lot assurance.

Retatrutide is the strongest relative line in the supplied record, while Semaglutide sits in a cautious middle zone. CJC-1295 is the clearest avoid signal, and Tirzepatide shows why a headline rating can flatter a fail-heavy pass/fail count. Ratings also contract under stricter grading, making dose-accuracy tolerance central to any buyer decision.

The non-lab evidence is less about a single scandal than about missing accountability signals. Alpha-Gen product pages reviewed in the field showed NAD+ and GLP-1 Retatrutide listings but no visible batch IDs or third-party COA links; the field materials also state that all Finnrick-tested Alpha-Gen samples lacked batch IDs. A shipping-policy URL leak ties Alpha-Gen’s current site materials to the older Accelerated Laboratory environment, while that Accelerated domain is now inactive.

The personnel and market footprint remain thin. Registry searches did not verify a matching Alpha-Gen Research entity or headquarters, WHOIS did not return usable registrant data, and Brian Asher is the strongest open-source personnel lead through an archived REDCON1 affiliate-code trail rather than a corporate filing. A legal sweep found no FDA action or litigation, and the current X/web scan did not document an active public Alpha-Gen promotion network.

Inside the full report:

  • Per-product pass/fail rates, methodology-divergence charts and Appendix A lab rows for the full tested catalog
  • Testing-date caveat and freshness analysis for Finnrick and GLP-1 Forum signals
  • Timeline exhibits showing the Alpha-Gen to Accelerated Laboratory shipping-policy URL artifact
  • Registry, WHOIS and brand-confusion checks for Alpha-Gen Research and adjacent Alpha/Accelerated names
  • Brian Asher attribution analysis using archived affiliate-code and current Linktree evidence
  • GLP-1 Forum Group 6 supply-chain clustering with Loti Labs and Suaway Lab Research

Risk assessment

  • Product-quality risk for CJC-1295, BPC-157, Ipamorelin and Tirzepatide — high: Finnrick’s Alpha-Gen set is fail-heavy overall (13 pass / 17 fail); CJC-1295 is 0 pass / 5 fail at 19.01%, and BPC-157, Ipamorelin and Tirzepatide are each fail-heavy.
  • Batch-ID and COA traceability risk — high: All 30 Finnrick-tested Alpha-Gen samples lacked batch IDs, and reviewed product pages including Retatrutide did not publish batch-specific third-party COAs.
  • Corporate-accountability and brand-lineage opacity risk — medium: No matching public registration or headquarters was verified; WHOIS failed, and Brian Asher/operator linkage remains an evidence-based inference rather than a filing.
  • Brand-confusion and authenticity-verification risk — medium: Alpha-Gen publishes no official-channel list, reseller list, batch lookup or verifiable COA path while dormant/unrelated Alpha/Accelerated assets can confuse buyers.
  • Supply-chain recency risk — medium: GLP-1 Forum Group 6 analysis flags zero data after September 2025, and field researchers found no new Finnrick Alpha-Gen results in the past 30 days.